Literature DB >> 11717538

Ets-1 mRNA expression in effusions of serous ovarian carcinoma patients is a marker of poor outcome.

B Davidson1, B Risberg, I Goldberg, J M Nesland, A Berner, C G Tropé, G B Kristensen, M Bryne, R Reich.   

Abstract

Ets-1 proto-oncogene is a transcription factor with a role in the activation of metastasis-associated molecules. We recently found that Ets-1 mRNA expression in solid tumors is a marker of poor prognosis in ovarian carcinoma. The objective of this study was to compare the expression of Ets-1 mRNA in effusions and primary and metastatic tumors of serous ovarian carcinoma patients and to evaluate its prognostic role in effusions. Sections from 67 malignant effusions and 90 primary and metastatic lesions were evaluated for expression of Ets-1 using mRNA in situ hybridization. Expression of Ets-1 mRNA was detected in carcinoma cells in 24 of 67 (36%) effusions. Expression in cancer cells was similar in peritoneal and pleural effusions. In solid lesions Ets-1 expression was detected in both tumor cells and stromal cells in 34 of 90 (38%) lesions. Ets-1 expression in tumor cells showed a strong association with that of stromal cells (p <0.001). Ets-1 expression in effusions showed an association with mRNA expression of basic fibroblast growth factor, previously studied in this patient cohort (p = 0.019). Ets-1 expression in solid lesions showed an association with mRNA expression of vascular endothelial growth factor (p <0.001 for both carcinoma and stromal cells), basic fibroblast growth factor (p = 0.007 for carcinoma cells, p = 0.006 for stromal cells), and interleukin-8 (IL-8) (p = 0.001 for tumor cells). Ets-1 mRNA showed upregulation in metastases when compared with effusion specimens (p = 0.028). In univariate survival analysis Ets-1 expression in carcinoma cells in effusions correlated with poor survival (p = 0.003). Our findings confirm the role of Ets-1 as a novel prognostic marker in advanced-stage ovarian carcinoma and extend it to effusion specimens. The elevated expression in solid metastases supports a central role in tumor progression as well. The association between Ets-1 mRNA expression and the expression of angiogenic genes, documented also in our previous study, points to the close link between these molecules, in agreement with the role of angiogenic genes in the transcriptional activation of Ets-1. The identical phenotype of carcinoma cells in pleural and peritoneal effusions provides further evidence for our theory that cells at these sites share similar genotypic and phenotypic profiles.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11717538     DOI: 10.1097/00000478-200112000-00004

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  11 in total

Review 1.  Function of PEA3 Ets transcription factors in mammary gland development and oncogenesis.

Authors:  Natasza A Kurpios; Nancy A Sabolic; Trevor G Shepherd; Gina M Fidalgo; John A Hassell
Journal:  J Mammary Gland Biol Neoplasia       Date:  2003-04       Impact factor: 2.673

2.  EMMPRIN (extracellular matrix metalloproteinase inducer) is a novel marker of poor outcome in serous ovarian carcinoma.

Authors:  Ben Davidson; Iris Goldberg; Aasmund Berner; Gunnar B Kristensen; Reuven Reich
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

3.  PEA3 is necessary for optimal epidermal growth factor receptor-stimulated matrix metalloproteinase expression and invasion of ovarian tumor cells.

Authors:  Karen D Cowden Dahl; Reema Zeineldin; Laurie G Hudson
Journal:  Mol Cancer Res       Date:  2007-05-02       Impact factor: 5.852

4.  The clinical role of the PEA3 transcription factor in ovarian and breast carcinoma in effusions.

Authors:  Ben Davidson; Iris Goldberg; Liora Tell; Sophya Vigdorchik; Mark Baekelandt; Aasmund Berner; Gunnar B Kristensen; Reuven Reich; Juri Kopolovic
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

5.  Expression of the 67 kDa laminin receptor and the alpha6 integrin subunit in serous ovarian carcinoma.

Authors:  Vered Givant-Horwitz; Ben Davidson; Gregg van de Putte; Hiep Phuc Dong; Iris Goldberg; Sivan Amir; Gunnar B Kristensen; Reuven Reich
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

6.  Matrix metalloproteinases (MMP), EMMPRIN (extracellular matrix metalloproteinase inducer) and mitogen-activated protein kinases (MAPK): co-expression in metastatic serous ovarian carcinoma.

Authors:  Ben Davidson; Vered Givant-Horwitz; Philip Lazarovici; Björn Risberg; Jahn M Nesland; Claes G Trope; Erik Schaefer; Reuven Reich
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

7.  Ets-1 regulates energy metabolism in cancer cells.

Authors:  Meghan L Verschoor; Leigh A Wilson; Chris P Verschoor; Gurmit Singh
Journal:  PLoS One       Date:  2010-10-22       Impact factor: 3.240

8.  Ets-1 gene expression in patients with thymoma.

Authors:  Hidefumi Sasaki; Yoshihiro Kobayashi; Masayuki Tanahashi; Haruhiro Yukiue; Motoki Yano; Masahiro Kaji; Masanobu Kiriyama; Ichiro Fukai; Yosuke Yamakawa; Yoshitaka Fujii
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2002-12

9.  Ets-1 mediates upregulation of Mcl-1 downstream of XBP-1 in human melanoma cells upon ER stress.

Authors:  L Dong; C C Jiang; R F Thorne; A Croft; F Yang; H Liu; C E de Bock; P Hersey; X D Zhang
Journal:  Oncogene       Date:  2011-03-21       Impact factor: 9.867

10.  Ets-1 regulates intracellular glutathione levels: key target for resistant ovarian cancer.

Authors:  Meghan L Verschoor; Gurmit Singh
Journal:  Mol Cancer       Date:  2013-11-15       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.